NEW YORK (GenomeWeb) – Seres Therapeutics announced today that it has formed a multi-year strategic alliance with Memorial Sloan Kettering Cancer Center (MSKCC) to discover and develop microbiome drugs that improve cancer therapies.

Specifically, the partners will use bacteria from the human microbiome to prevent transplant-related infections and graft-versus-host disease in patients undergoing hematopoietic stem cell transplantation (HSCT)-based cancer treatment. They also hope to increase the safety and efficacy of checkpoint inhibitor-based cancer immunotherapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.